Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia
Acta Haematologica, 04/13/2012Nardinelli L et al.
The 5–year event–free and overall survival analyses revealed no significant differences between the groups. These data imply that knowledge of the pretherapeutic level of hOCT1 (human organic cation transporter 1) could be a useful marker to predict IM therapy outcome in treatment–naïve chronic–phase (CP) chronic myeloid leukemia (CML) patients.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.